INTERCEPT-T2D project: personalising type 2 diabetes prevention and treatment through inflammation research
Safety Classified by Officially
Type 2 diabetes (T2D) develops when the pancreas can no longer produce enough insulin to offset the body’s declining sensitivity to it. Because the underlying causes of both poor insulin secretion and insulin resistance vary from person to person, the disease progresses differently in different patients, making it hard to predict who will develop serious complications. A critical turning point in T2D is the onset of complications such as cardiovascular disease, kidney damage, eye disease, nerve damage and fatty liver disease, which are major drivers of disability and early death.
Chronic low-grade inflammation may be one of the key early triggers of these complications. The Horizon Europe INTERCEPT-T2D project found that some patients already show a distinct inflammatory pattern at the time of diagnosis, both in the body as a whole and in pancreatic islets, where it may directly impair insulin-producing beta cells.
The project has identified four distinct immunometabolic subgroups (called endotypes) in type 2 diabetes, using routine blood counts. The findings show that these immune profiles are linked to different disease trajectories, with two of them associated with higher risks of cardiovascular and kidney complications and mortality. Because these endotypes can be detected early, remain relatively stable over time and rely on standard full blood count measures, they offer a practical way to identify patients at risk, personalise prevention measures and adjust treatments.
On World Diabetes Day, HaDEA interviewed Nicolas Venteclef, Group Leader, Immunity and Metabolism of Diabetes at the Institut Necker Enfants Malades.
Could you briefly present the project and its main objectives in improving understanding, prevention and care of type 2 diabetes?
This is an extract. The publication continues at the source.
© European Union — excerpt, reused under CC BY 4.0. Licence
Read the original at the source: https://hadea.ec.europa.eu/news/intercept-t2d-project-personalising-type-2-diabetes-prevention-and-treatment-through-inflammation-2026-11-13_en
Officially imported this from European Health and Digital Executive Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Health and Digital Executive Agency — imported from official source
- Official source
- https://hadea.ec.europa.eu/node/2/rss_en RSS
- Imported
- November 13, 2026 17:02
- Versions
- 1 recorded
- Identity
-
https://hadea.ec.europa.eu/news/intercept-t2d-project-personalising-type-2-diabetes-pre...